Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)

  1. Rades, Dirk
  2. Bartscht, Tobias
  3. Hunold, Peter
  4. Schmidberger, Heinz
  5. König, Laila
  6. Debus, Jürgen
  7. Belka, Claus
  8. Homann, Nils
  9. Spillner, Patrick
  10. Petersen, Cordula
  11. Kuhnt, Thomas
  12. Fietkau, Rainer
  13. Ridwelski, Karsten
  14. Karcher-Kilian, Kerstin
  15. Kranich, Anne
  16. Männikkö, Sofia
  17. Schild, Steven E.
  18. Maderer, Annett
  19. Moehler, Markus

Download
s00066-020-01646-4.pdf 954,17KB
WeightNameValue
1000 Titel
  • Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)
1000 Autor/in
  1. Rades, Dirk |
  2. Bartscht, Tobias |
  3. Hunold, Peter |
  4. Schmidberger, Heinz |
  5. König, Laila |
  6. Debus, Jürgen |
  7. Belka, Claus |
  8. Homann, Nils |
  9. Spillner, Patrick |
  10. Petersen, Cordula |
  11. Kuhnt, Thomas |
  12. Fietkau, Rainer |
  13. Ridwelski, Karsten |
  14. Karcher-Kilian, Kerstin |
  15. Kranich, Anne |
  16. Männikkö, Sofia |
  17. Schild, Steven E. |
  18. Maderer, Annett |
  19. Moehler, Markus |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-12
1000 Erschienen in
1000 Quellenangabe
  • 196(9):795-804
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00066-020-01646-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449950/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!To investigate the efficacy and toxicity of cetuximab when added to radiochemotherapy for unresectable esophageal cancer.!##!Methods!#!This randomized phase 2 trial (clinicaltrials.gov, identifier NCT01787006) compared radiochemotherapy plus cetuximab (arm A) to radiochemotherapy (arm B) for unresectable esophageal cancer. Primary objective was 2‑year overall survival (OS). Arm A was considered insufficiently active if 2‑year OS was ≤40% (null hypothesis = H!##!Results!#!Two-year OS was 71% in arm A (95% CI: 55-87%) vs. 53% in arm B (95% CI: 36-71%); H!##!Conclusion!#!Given the limitations of this trial, radiochemotherapy plus cetuximab was feasible. There was a trend towards improved PFS and MFS. Larger studies are required to better define the role of cetuximab for unresectable esophageal cancer.
1000 Sacherschließung
lokal Antineoplastic Agents, Immunological/adverse effects [MeSH]
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Esophageal Neoplasms/therapy [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal EGFR antibody
lokal Progression-Free Survival [MeSH]
lokal Middle Aged [MeSH]
lokal Cetuximab/therapeutic use [MeSH]
lokal Efficacy
lokal Original Article
lokal Feasibility
lokal Male [MeSH]
lokal Antineoplastic Agents, Immunological/therapeutic use [MeSH]
lokal Disease-Free Survival [MeSH]
lokal Esophageal cancer
lokal Cetuximab/adverse effects [MeSH]
lokal Chemoradiotherapy/adverse effects [MeSH]
lokal Definitive treatment
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UmFkZXMsIERpcms=|https://frl.publisso.de/adhoc/uri/QmFydHNjaHQsIFRvYmlhcw==|https://frl.publisso.de/adhoc/uri/SHVub2xkLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/U2NobWlkYmVyZ2VyLCBIZWlueg==|https://frl.publisso.de/adhoc/uri/S8O2bmlnLCBMYWlsYQ==|https://frl.publisso.de/adhoc/uri/RGVidXMsIErDvHJnZW4=|https://frl.publisso.de/adhoc/uri/QmVsa2EsIENsYXVz|https://frl.publisso.de/adhoc/uri/SG9tYW5uLCBOaWxz|https://frl.publisso.de/adhoc/uri/U3BpbGxuZXIsIFBhdHJpY2s=|https://frl.publisso.de/adhoc/uri/UGV0ZXJzZW4sIENvcmR1bGE=|https://frl.publisso.de/adhoc/uri/S3VobnQsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/RmlldGthdSwgUmFpbmVy|https://frl.publisso.de/adhoc/uri/Umlkd2Vsc2tpLCBLYXJzdGVu|https://frl.publisso.de/adhoc/uri/S2FyY2hlci1LaWxpYW4sIEtlcnN0aW4=|https://frl.publisso.de/adhoc/uri/S3JhbmljaCwgQW5uZQ==|https://frl.publisso.de/adhoc/uri/TcOkbm5pa2vDtiwgU29maWE=|https://frl.publisso.de/adhoc/uri/U2NoaWxkLCBTdGV2ZW4gRS4=|https://frl.publisso.de/adhoc/uri/TWFkZXJlciwgQW5uZXR0|https://frl.publisso.de/adhoc/uri/TW9laGxlciwgTWFya3Vz
1000 Hinweis
  • DeepGreen-ID: 38789fee0a374597a71c5a6e86904bd7 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6441797.rdf
1000 Erstellt am 2023-04-25T18:32:04.402+0200
1000 Erstellt von 322
1000 beschreibt frl:6441797
1000 Zuletzt bearbeitet Thu Oct 19 11:10:20 CEST 2023
1000 Objekt bearb. Thu Oct 19 11:10:20 CEST 2023
1000 Vgl. frl:6441797
1000 Oai Id
  1. oai:frl.publisso.de:frl:6441797 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source